Zacks: Brokerages Expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Will Post Earnings of -$0.76 Per Share

Analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to announce ($0.76) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.80) to ($0.71). Lexicon Pharmaceuticals reported earnings of ($0.16) per share during the same quarter last year, which would indicate a negative year over year growth rate of 375%. The firm is expected to issue its next earnings results on Wednesday, March 11th.

On average, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.79 per share for the current year, with EPS estimates ranging from $0.71 to $0.87. For the next fiscal year, analysts forecast that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.40) to ($1.94). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The firm had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. During the same period in the previous year, the business earned ($0.26) earnings per share. The company’s revenue for the quarter was up 4124.5% compared to the same quarter last year.

LXRX has been the subject of a number of analyst reports. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Gabelli cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. They noted that the move was a valuation call. Wedbush reiterated a “buy” rating and issued a $17.00 target price on shares of Lexicon Pharmaceuticals in a research note on Sunday, December 22nd. Citigroup lowered Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their target price for the company from $3.00 to $4.00 in a research note on Friday, November 8th. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Eight analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $6.50.

NASDAQ LXRX opened at $4.28 on Friday. Lexicon Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $8.39. The stock has a market cap of $428.28 million, a price-to-earnings ratio of 2.96 and a beta of 1.02. The business has a fifty day moving average of $4.22 and a 200-day moving average of $3.60. The company has a quick ratio of 8.01, a current ratio of 8.11 and a debt-to-equity ratio of 1.42.

Institutional investors have recently added to or reduced their stakes in the stock. Pictet Asset Management Ltd. boosted its holdings in Lexicon Pharmaceuticals by 9.6% in the third quarter. Pictet Asset Management Ltd. now owns 729,876 shares of the biopharmaceutical company’s stock valued at $2,197,000 after purchasing an additional 64,100 shares during the last quarter. Millennium Management LLC increased its stake in shares of Lexicon Pharmaceuticals by 4.5% in the third quarter. Millennium Management LLC now owns 1,220,629 shares of the biopharmaceutical company’s stock worth $3,674,000 after purchasing an additional 53,092 shares during the period. Vanguard Group Inc. increased its stake in shares of Lexicon Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock worth $26,670,000 after purchasing an additional 319,382 shares during the period. Morgan Stanley increased its stake in shares of Lexicon Pharmaceuticals by 158.0% in the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock worth $1,229,000 after purchasing an additional 119,611 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in shares of Lexicon Pharmaceuticals in the third quarter worth about $202,000. Hedge funds and other institutional investors own 96.24% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: What does RSI mean?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.